• * INSTRUCTIONS: Select any Filter to change News and Search: 
• Hepatology
• Hepatologist
• Liver
• Pancreas
• Gall-Bladder
• Bile-Duct
• Gastroenterology
• Oncology
• Procedures
• ERCP
• TPC
• TIPSS
• Liver-Disease
• Liver-Cancer
• Cirrhosis
• Alcohol-Consumption
• Hepatitis
• Jaundice
• Gall-Stone
• Pancreatitis
• Blood
• Transfusion
• Drug-Overdose

Common Hepatology Symptoms

• Jaundice (Icterus) — Yellowing of the skin and sclera caused by elevated serum bilirubin levels due to impaired hepatic processing or biliary obstruction.
• Ascites — Pathologic accumulation of fluid in the peritoneal cavity, commonly secondary to portal hypertension and advanced liver cirrhosis.
• Hepatic Encephalopathy — Spectrum of neuropsychiatric abnormalities including confusion, asterixis, and altered consciousness resulting from neurotoxin accumulation.
• Pruritus — Severe, generalized skin itching frequently associated with cholestatic liver diseases and systemic bile acid accumulation.
• Right Upper Quadrant Abdominal Pain — Dull ache or sensation of fullness caused by stretching of Glisson's capsule surrounding an enlarged or inflamed liver.
• Spider Angiomas and Palmar ErytHepa — Vascular cutaneous signs stemming from altered sex hormone metabolism and hyperdynamic circulation in chronic liver disease.
• Dark Urine and Acholic Stools — Tea-colored urine from bilirubinuria paired with pale, clay-colored stools indicating impaired biliary drainage.

Milestones in Hepatology History

• Discovery of the Australia Antigen (1965) — Baruch Blumberg identified the surface antigen of Hepatitis B, paving the way for diagnostic screening and the first HBV vaccine.
• First Successful Human Liver Transplant (1967) — Dr. Thomas Starzl performed the world's first successful human liver transplantation at the University of Colorado Health Sciences Center.
• Identification of Hepatitis Delta Virus (1977) — Mario Rizzetto discovered the delta antigen, characterizing HDV as a defective subviral pathogen reliant on HBV co-infection.
• Cloning and Identification of Hepatitis C (1989) — Michael Houghton, Harvey Alter, and Charles Rice isolated the non-A, non-B hepatitis virus, officially naming it Hepatitis C.
• Introduction of MELD Score System (2002) — The Model for End-Stage Liver Disease was adopted in the United States to prioritize liver allocation based on 3-month mortality risk.
• Approval of Direct-Acting Antivirals for HCV (2013) — The FDA approved Sofosbuvir, ushering in an era of highly effective, interferon-free oral curative regimens for chronic Hepatitis C.
• Nomenclature Shift to MASLD and MASH (2023) — Global liver societies renamed NAFLD/NASH to better reflect underlying metabolic pathology and eliminate stigmatizing language.

Current Hepatology Research

• Bepirovirsen Functional Cure Trials — Evaluating antisense oligonucleotides to achieve a sustained loss of HBsAg and drug-free clinical response in patients living with chronic hepatitis B.
• MASLD Diagnostics and Screening — Refining non-invasive biomarker panels and metabolic criteria to detect metabolic dysfunction-associated steatotic liver disease early in co-infected populations.
• Hepatitis D Expanded Testing Protocols — Implementing reflexive antibody and RNA testing strategies to address global underdiagnosis of delta hepatitis co-infections.
• Global Elimination Strategy Implementation — Tracking regional epidemiological data and public health interventions designed to accelerate viral hepatitis eradication goals.
• RNA Interference (RNAi) Gene Silencing — Investigating small interfering RNA therapies to knock down viral transcripts and reduce antigen production in chronic liver infections.
• MASH Fibrosis Biomarker Development — Validating novel serum panels and elastography metrics to monitor metabolic dysfunction-associated steatohepatitis regression without invasive biopsies.
• In Vivo Gene Editing via Lipid Nanoparticles — Utilizing hepatic-targeted LNP delivery systems to correct monogenic metabolic liver disorders directly within host hepatocytes.
• Gut Microbiome Alterations in Cirrhosis — Analyzing gut-liver axis dysbiosis to prevent bacterial translocation and manage portal hypertension complications in end-stage liver disease.